SYNTHORX INC. - COMMON STOCK (THOR)
(Delayed Data from NSDQ)
$17.04 USD
+0.23 (1.37%)
Updated May 3, 2019 04:00 PM ET
After-Market: $16.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.04 USD
+0.23 (1.37%)
Updated May 3, 2019 04:00 PM ET
After-Market: $16.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Can Winnebago Replicate This Year's Stellar Show in 2020?
by Zacks Equity Research
Winnebago (WGO) looks well poised to maintain this year's momentum in the New Year, courtesy of its leadership position in the industry, game-changing acquisitions and solid financials.
Biotech Leading in Q4: Best ETFs & Stocks
by Sweta Killa
We highlight five biotech ETFs and stocks that are leading the market in Q4.
Moving Average Crossover Alert: Synthorx
by Zacks Equity Research
Synthorx, Inc. (THOR) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Why Biotech ETFs are Surging to New Highs
by Neena Mishra
increasing M&A deals and cutting edge therapies are driving biotech ETFs higher
Biotech ETFs Hit New Highs on Deal Activities
by Sweta Killa
Following the new deals in the healthcare space, a few biotech ETFs hit new highs.
Company News for Dec 10, 2019
by Zacks Equity Research
Companies in the news are: ARQL, THOR, CGC, FATE
Sanofi Unveils Growth Strategy, Ends Diabetes & CV Research
by Zacks Equity Research
Sanofi (SNY) to prioritize key growth drivers, improve operating efficiencies and generate cost savings. The company discontinues R&D activities in diabetes and cardiovascular segments.
Pharma M&As Continue, Merck, Sanofi to Buy Cancer Drug Firms
by Kinjel Shah
Merck offers to buy ArQule for $2.7 billion while Sanofi signs a definitive deal to purchase Synthorx for $2.5 billion.
Week Begins with Biotech Mergers
by Zacks Equity Research
Week Begins with Biotech Mergers
Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More
by Mark Vickery
Large-cap pharmaceutical companies are putting their assets to work in the biotech space, particularly in cancer treatment (oncology).
Sanofi to Buy Synthorx for $2.5B to Boost Cancer Portfolio
by Zacks Equity Research
Sanofi (SNY) offers to buy Synthorx (THOR) for $2.5 billion. The deal will add Synthorx's lead pipeline asset, THOR-707 to Sanofi's oncology portfolio.
Will Synthorx Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Synthorx.
Synthorx's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Synthorx.